News >

Expert Discusses Optimizing CDK 4/6 Inhibitors in Breast Cancer

Angelica Welch
Published: Wednesday, Mar 28, 2018

Reshma Mahtani, DO

Reshma Mahtani, DO
There are 3 approved CDK 4/6 inhibitors for the treatment of patients with metastatic breast cancer, and the decision of which one to use and when should be made on an individualized basis, explains Reshma Mahtani, DO.

The most recent of the 3, abemaciclib (Verzenio), was approved in February 2018 for use in combination with an aromatase inhibitor (AI) for the frontline treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication